Serina Therapeutics Moves Forward with SER-252 Program
Serina Therapeutics, Inc. is making strides in its quest to develop SER-252, a novel treatment targeting advanced Parkinson's disease. Recognized on the NYSE American under the ticker SER, Serina is taking significant steps following the submission of a complete response to the FDA regarding a clinical hold. This letter was initially prompted due to specific inquiries about the formulation excipient in their drug application.
FDA Clinical Hold and Resolution Efforts
Recently, the U.S. Food and Drug Administration (FDA) issued a clinical hold on Serina's Investigational New Drug (IND) application for SER-252. The hold arose following the need for additional clarity on the formulation excipient used in the drug. In response, Serina worked diligently to compile a comprehensive data package to address the Agency's concerns.
Key Components of the Response
The complete response submitted by Serina includes crucial information supporting the use of trehalose as a subcutaneous excipient. This data encompasses a comparison with other approved products that feature trehalose and insights from nonclinical analyses. Moreover, a revised research protocol is proposed to initiate the single ascending dose (SAD) phase of the SER-252-1b trial, anticipating to take off in the first quarter of 2026.
Importance of Continued Engagement with the FDA
Steve Ledger, CEO of Serina Therapeutics, expressed the company's commitment to addressing the FDA’s questions thoroughly. The engaging dialogue with the Agency is critical as they advance towards initiating the registrational study for SER-252.
Global Start-Up Initiatives for Clinical Trials
Despite the clinical hold, Serina has not paused its global initiatives for the SER-252 trial. The company remains active in site start-up activities across various regions, including Australia, where they have garnered substantial support from local investigators and the Parkinson’s community. Such groundwork is pivotal in ensuring robust participation for the planned trial.
Anticipated Milestones and Future Directions
Serina aims to have its first patient enrolled by early 2026, contingent upon receiving the necessary approvals. This milestone will be a significant step towards demonstrating the potential of SER-252 in providing much-needed therapeutic options for those suffering from advanced Parkinson's disease. The company's strategic preparations also include obtaining regulatory and ethical approvals, aligning their goals with patient needs.
Understanding Serina’s Innovative POZ Platform
At the heart of Serina Therapeutics' development strategy lies its proprietary POZ Platform, a cutting-edge drug optimization technology. This platform utilizes poly (2-oxazoline), a synthetic, water-soluble polymer designed to enhance the efficacy and safety of drugs delivered through subcutaneous injections. The benefits of this technology are especially pertinent for drugs that have previously faced limitations due to adverse pharmacokinetic profiles, including toxicity and short half-lives.
Diverse Applications and Future Collaborations
Serina’s POZ platform holds promise across a variety of therapeutic applications, and the company is enthusiastic about potential out-licensing or co-development partnerships. Their agreement with Pfizer, Inc. serves as a testament to the platform's versatility in lipid nanoparticle drug delivery systems.
Insights into SER-252 and Its Potential
SER-252 is an investigational therapy designed to provide continuous dopaminergic stimulation (CDS), aiming to alleviate symptoms associated with Parkinson's disease. Preclinical data suggest that this treatment could minimize common side effects such as skin reactions, often associated with similar therapies, enhancing patient comfort and adherence.
Frequently Asked Questions
What is SER-252?
SER-252 is an investigational drug developed by Serina Therapeutics aimed at treating advanced Parkinson's disease.
What challenges did Serina face with the FDA?
The FDA placed a clinical hold on Serina’s IND application for SER-252 due to questions about the formulation excipient.
What is the POZ Platform?
The POZ Platform is Serina's proprietary technology that enhances the efficacy and safety profiles of various drug modalities.
What are the anticipated developments for SER-252?
Serina anticipates starting the single ascending dose phase of the SER-252-1b trial in early 2026, pending FDA approvals.
Where is Serina Therapeutics headquartered?
Serina Therapeutics is based in Huntsville, Alabama, at the HudsonAlpha Institute of Biotechnology.
